Oncology
Asymptomatic Myeloma
11
Pipeline Programs↗
0
Active Trials↗
6
Companies Involved↗
Asymptomatic Myeloma is an emerging landscape with 11 programs across 6 companies. The most active players are Roche, Merck & Co., Pfizer. 4 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 24
Phase 31
Analysis
Modality Breakdown
11programs
Small molecule655%
Monoclonal antibody545%
Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
3
clinical trials
Terminated3 · 100%
Clinical Trials
Trial Activity
Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma
Terminated·—·Phase 2·NCT01096810·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)